We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00583128
Recruitment Status : Completed
First Posted : December 31, 2007
Last Update Posted : June 18, 2014
Information provided by (Responsible Party):
Ocera Therapeutics

December 20, 2007
December 31, 2007
June 18, 2014
August 2007
May 2010   (Final data collection date for primary outcome measure)
  • Percent of patients who achieve at least a 50% reduction in the number of days with abdominal pain during the final 2 weeks of the double-blind treatment course. [ Time Frame: Eight weeks ]
  • Safety endpoint is adverse events (AEs) deemed possibly, probably, or definitely related to treatment with investigational product during the double-blind treatment course. [ Time Frame: 8 weeks ]
Same as current
Complete list of historical versions of study NCT00583128 on ClinicalTrials.gov Archive Site
  • Percent change in the IBS QOL score. [ Time Frame: Eight weeks ]
  • Percent change in HADS score. [ Time Frame: 8 weeks ]
  • Percent change in Bristol Scale score. [ Time Frame: 8 weeks ]
  • Percent change in individual items in the IBS Symptom Severity questionnaire. [ Time Frame: 8 weeks ]
  • Durability of effect after the first eight weeks of treatment. [ Time Frame: 8 weeks ]
  • Change in clinical laboratory tests from Baseline to Week 8 and to Week 18. [ Time Frame: 8 weeks ]
  • Any adverse event occurring after Week 8. [ Time Frame: 8 weeks ]
  • Physical examinations, vital signs (blood pressure, heart rate, respiration and temperature). [ Time Frame: 8 weeks ]
Same as current
Not Provided
Not Provided
Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome
A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome
The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with non-constipating IBS. The study will test whether or not patients receiving AST-120 experience at least a 50% reduction in the number of days with abdominal pain compared to placebo.

Patients experiencing non-constipating IBS will be randomized to one of two arms in the study: the experimental drug AST-120 or placebo. Patients will take 2g of AST-120 or placebo three times per day for eight weeks. After the 8 week course, patients will receive an additional 8 weeks single blind treatment, after a one week washout period.

The experimental drug AST-120 is composed of black, odorless spherical carbon particles in 2g sachets (aluminum foil pouches). The placebo consists of microcrystalline cellulose spheres, Celphere CP-305 stained to match the appearance of AST-120, in 2g sachets (aluminum foil pouches). Both AST-120 and placebo are oral (taken by mouth) preparations. Both are tasteless. To take the product, patients will tear open the sachet, drop the contents directly on their tongue and wash it down with 8 ounces of water.

Patients will be expected to participate in up to 10 visits, approximately three by telephone and the remainder of visits are in-clinic. At these visits, patients will undergo a number of tests including: hematology panel, lactose intolerance testing, physical exams, pregnancy tests, evaluations based on the following scales: The Bristol Stool Scale, IBS Severity Scale, IBS Quality of Life, SCL-90R.

Provided the patient has been stable for eight weeks prior to their baseline visit, they will be allowed to take the following medications: drugs that inhibit gastric secretion (histamine blockers, proton pump inhibitors), benzodiazepines and Imidazopyridines (short acting, nonbenzodiazepine hypnotics) for sleep (dose must be consistent with the use of a sleep agent) aspirin at a cardiovascular prophylactic dose (75-150 mg/day) and paracetamol. Antidepressants for non-IBS symptoms are allowed. Loperamide will be permitted as a rescue for diarrhea only when patients are experiencing at least 3 liquid or soft stools in one day. However, Loperamide is prohibited during the two week screening period.

Patients will not be allowed to take the following medications whilst on trial and these therapies must have been discontinued by at least two weeks prior to their baseline visit: probiotics, neuroleptics, antidepressants for IBS symptoms, daytime tranquilizers, prokinetics, spasmolytics, analgesics, other investigational agents and any over-the-counter medications.

Patient will be required to keep a diary during the study

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Irritable Bowel Syndrome
  • Drug: AST-120
    oral, sachet, 2 grams three times daily for 8 weeks
  • Drug: Celphere® CP-305
    oral, placebo, sachet, 2 grams three times daily for 8 weeks
  • Experimental: 1
    AST-120, 2 gram sachets
    Intervention: Drug: AST-120
  • Placebo Comparator: 2
    Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
    Intervention: Drug: Celphere® CP-305

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2010
May 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Body weight ≥ 40 kg;
  • Recurrent abdominal pain or discomfort for three or more days per month for the last three months which meets Rome III criteria for non-constipating IBS;
  • Patients on a stable diet for at least eight weeks;
  • Patients ≥ 50 years of age with a negative screening colonoscopy in the last five years;
  • Able and willing to comply with all protocol procedures for the planned duration of the study;
  • Able and willing to understand, sign and date an informed consent document, and authorize access to protected health information,
  • Females must be postmenopausal, surgically incapable of bearing children, or practicing a reliable method of birth control (intrauterine devices, spermicide and barrier) (Hormonal contraceptives are NOT regarded as adequate for the purpose of this trial.) Partner/spouse sterility may also qualify at the Investigator's discretion. Females of child-bearing potential must have a negative urine pregnancy test at baseline.

Exclusion Criteria:

  • Constipating IBS;
  • History of untreated lactose intolerance;
  • History of colonic or major abdominal surgery (colectomy, for example);
  • Active (untreated) Thyroid disease;
  • Current diagnosis of major depression or psychosis;
  • Known positive stool cultures for Clostridium difficile or other pathogens;
  • Any condition necessitating the administration of analgesics (except paracetamol), probiotics, neuroleptics, antidepressants for IBS symptoms, daytime tranquilizers, prokinetics or spasmolytic medications;
  • Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling;
  • Other major physical or major psychiatric illness within the last six months that in the opinion of the investigator would affect the patient's ability to complete the trial;
  • Uncontrolled systemic disease such as diabetes;
  • Patients undergoing chemotherapy for the treatment of cancer;
  • Known hypersensitivity or contraindication to any component of the test product (study drugs) or diagnostics used;
  • Participation in another study within eight (8) weeks prior to the study;
  • Unable to attend all visits required by the protocol;
  • Female patients must be excluded if they are pregnant, breast feeding, or planning to become pregnant during the study.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Belgium,   United States
Not Provided
Not Provided
Ocera Therapeutics
Ocera Therapeutics
Not Provided
Principal Investigator: Jan Tack, MD University of Leuven, Department of Gastroenterology
Ocera Therapeutics
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP